Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study
JNCI: Journal of the National Cancer Institute · 01.11.2025 · 117 (11) · 2362-2371
DOI: 10.1093/jnci/djaf229 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 20.08.2025. Verfasst von Aziz Zaanan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Digestive Oncology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris (APHP), University o…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Background
In RAS wild-type (WT) metastatic colorectal cancer (mCRC), preliminary data have suggested that circulating tumor DNA (ctDNA) may select patients for anti-EGFR rechallenge therapy.
Methods
RASINTRO is a prospective nonrandomized study evaluating anti-EGFR rechallenge strategy in third and later line treatment in RAS/BRAF WT mCRC. Liquid biopsies for ctDNA analysis were collected before the first (C1) and second (C2) cycles of anti-EGFR rechallenge therapy. The primary endpoint was the progression-free survival (PFS) according to RAS/BRAF mutational status on ctDNA at C1.
Results
Among 74 patients screened between November 2017 and March 2020, 62 were enrolled: median age, 66.1 years; median number of previous lines of therapy, 3; panitumumab or cetuximab rechallenge alone (66.2%) or with chemotherapy (33.8%); ctDNA RAS/BRAF status at C1, 42 WT (67.7%) and 20 mutated (32.3%). Median PFS (3.3 vs 1.9 months: hazard ratio (HR) = 0.43; P <.01) and overall survival (OS) (7.9 vs 4.9 months; HR = 0.46; P =.01) were significantly longer for patients with ctDNA RAS/BRAF WT vs mutated at C1. Among the 32 patients with ctDNA RAS/BRAF WT at C1 and available blood samples at C2, those who have experienced an early decrease of >50% in ctDNA concentration (n = 15) had a significantly longer median PFS (4.2 vs 2.8 months; HR = 0.39; P =.01) and OS (10.2 vs 4.2 months; HR = 0.39; P =.02).
Conclusion
This study showed that anti-EGFR rechallenge therapy in refractory disease is more effective in patients with RAS/BRAF WT on ctDNA, and in those who experienced an early decrease of >50% in ctDNA concentration Trial Registration ClinicalTrials.gov Identifier: NCT03259009.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Digestive Oncology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris (APHP), University of Paris Cité, Paris, France.
- Centre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université Paris Cité, Paris, France.
- Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
- Department of Digestive Oncology, Centre Antoine Lacassagne, Nice, France.
- Methodology and Quality of Life Unit in Oncology, Centre Hospitalier Universitaire (CHU) Besançon, Hôpital Jean Minjoz, Besançon, France.
- Université de Franche-Comté, EFS, INSERM, UMR RIGHT, Besançon, France.
ORCID-Profile: Aziz Zaanan, Elisabeth Sophie Bergen, Pascal Artru, Thierry Lecomte, Olivier Bouché, Céline Lepère, Margherita Ambrosini, Romain Coriat, Astrid Lièvre, Romain Cohen, Samy Louafi, Jean-Baptiste Bachet, Sophie Goyer, Julien Taieb, Dewi Vernerey, Pierre Laurent-Puig
Förderung
- AstraZeneca
Zitieren
APA
Zaanan, A., Bergen, E. S., Evesque, L., Meurisse, A., Artru, P., Lecomte, T., Bouché, O., Lepère, C., Ambrosini, M., Coriat, R., Lièvre, A., Cohen, R., Boige, V., Louafi, S., Bachet, J. B., Goyer, S., Taieb, J., Vernerey, D., Blons, H., & Laurent-Puig, P. (2025). Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study. JNCI: Journal of the National Cancer Institute, 117(11), 2362-2371. https://doi.org/10.1093/jnci/djaf229
Vancouver
Zaanan A, Bergen ES, Evesque L, Meurisse A, Artru P, Lecomte T, et al. Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study. JNCI: Journal of the National Cancer Institute. 2025;117(11):2362-2371. doi:10.1093/jnci/djaf229
BibTeX
@article{Zaanan2025,
author = {Zaanan, Aziz and Bergen, Elisabeth Sophie and Evesque, Ludovic and Meurisse, Aurelia and Artru, Pascal and Lecomte, Thierry and Bouché, Olivier and Lepère, Céline and Ambrosini, Margherita and Coriat, Romain and Lièvre, Astrid and Cohen, Romain and Boige, Valérie and Louafi, Samy and Bachet, Jean-Baptiste and Goyer, Sophie and Taieb, Julien and Vernerey, Dewi and Blons, Hélène and Laurent-Puig, Pierre},
title = {Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
volume = {117},
number = {11},
pages = {2362--2371},
doi = {10.1093/jnci/djaf229}
}
EUVIMED